CAI Insider Trading
Caris Life Sciences, Inc. (CAI) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $8.35B, listed on NASDAQ, employing roughly 1,846 people, carrying a beta of 0.68 to the broader market. Caris Life Sciences, Inc. Led by David Dean Halbert, public since 2025-06-18.
In the last 12 months, Caris Life Sciences, Inc. insiders made 4 buy transactions and 7 sale transactions.
| Date | Name | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2026 | Denton John Russel | S-Sale | 7,500 | $31.82 | $238.6K |
| Sep 17, 2026 | Brille Brian J | M-Exempt | 400,000 | $2.44 | $976.0K |
| Sep 17, 2026 | Brille Brian J | M-Exempt | 400,000 | $2.44 | $976.0K |
| Sep 17, 2026 | Brille Brian J | S-Sale | 400,000 | $30.33 | $12.1M |
| Sep 4, 2026 | Spetzler David Baxley | M-Exempt | 1,000,000 | $2.44 | $2.4M |
| Sep 4, 2026 | Spetzler David Baxley | M-Exempt | 250,000 | $2.44 | $610.0K |
| Sep 4, 2026 | Spetzler David Baxley | S-Sale | 119,212 | $24.76 | $3.0M |
| Sep 4, 2026 | Spetzler David Baxley | S-Sale | 393,100 | $24.76 | $9.7M |
| Sep 4, 2026 | Spetzler David Baxley | S-Sale | 84,900 | $25.32 | $2.1M |
| Sep 4, 2026 | Spetzler David Baxley | M-Exempt | 1,000,000 | $2.44 | $2.4M |
CAI Insider Activity by Quarter
Reported Form 4 and Form 5 lines under CAI's own SEC company ID, by transaction date, back to Q4 2024. Purchases and sales are code P / S (open market or private) in the company's shares; other lines are purchases and sales of other securities (options, warrants, preferred), awards, exercises, tax withholding, gifts and other acquisitions and dispositions. Later filings and amendments can change the current quarter. Earlier quarters are not shown: the filings read reach back to Nov 14, 2005, and a quarter counts only when every filing for it was read. 346 lines filed under another SEC company ID are not counted.
| Quarter | Purchases | Bought | Sales | Sold | Other Lines |
|---|---|---|---|---|---|
| Q4 2026 (so far) | 0 | N/A | 0 | N/A | 0 |
| Q3 2026 | 0 | N/A | 5 | $27.2M | 14 |
| Q2 2026 | 2 | $1.5M | 0 | N/A | 7 |
| Q1 2026 | 0 | N/A | 0 | N/A | 13 |
| Q4 2025 | 2 | $110.3K | 2 | $1.7M | 5 |
| Q3 2025 | 0 | N/A | 0 | N/A | 8 |
| Q2 2025 | 2 | $787.5K | 0 | N/A | 33 |
| Q1 2025 | 0 | N/A | 0 | N/A | 8 |
| Q4 2024 | 0 | N/A | 0 | N/A | 0 |
Filings Under Another SEC Company ID
346 filing lines on file were filed under an SEC company ID (CIK) other than CAI's (2019410). Such a filing can be a predecessor company's (one that reorganized, redomiciled or converted files under a new CIK), a former holder of the CAI ticker's, or another company's that CAI or its insiders report holding; the CIK alone does not say which. They are not counted in the figures above.
| CIK | Lines | Dates | Securities |
|---|---|---|---|
| 1388430 | 139 | Oct 25, 2017 to Nov 22, 2021 | Stock Option (right to buy), Common Stock, Series A Fixed to Floating Rate Redeemable Preferred Stock |
| 16058 | 196 | Apr 27, 2000 to Oct 16, 2011 | CACI Common (RIght to Buy), CACI Common (Right to Buy), CACI Common Stock |
| 319687 | 11 | Sep 26, 2006 to May 15, 2007 | Common Stock, Outside Director Stock Option (Right to Buy) |
CAI Institutional Ownership (13F)
As of Jun 30, 2026 (Q2 2026), 246 institutions reported holding 154,105,427 CAI shares, valued at $2.75B as reported, 52.6% of its market cap (market cap of Jun 26, 2026). That is +44 institutions from the quarter before. Among managers whose reports for both quarters are comparable, 67 opened a position, 22 closed one, 105 added and 47 trimmed.
Top Holders, Q2 2026
| Manager | Shares | Value | Change |
|---|---|---|---|
| FMR LLC | 30,923,878 | $551.1M | +138,293 |
| J. H. Whitney Equity Partners VI, LLC | 11,256,615 | $200.6M | -7,000,000 |
| COATUE MANAGEMENT LLC | 9,819,992 | $175.0M | Unchanged |
| BRAIDWELL LP | 8,256,032 | $147.1M | +246,585 |
| Sixth Street Partners Management Company, L.P. | 7,327,041 | $130.6M | -7,058,358 |
| PointState Capital LP | 6,828,835 | $121.7M | -531,611 |
| JPMORGAN CHASE & CO | 6,558,514 | $120.2M | +3,098,299 |
| BlackRock, Inc. | 5,536,798 | $98.7M | +679,686 |
| T. Rowe Price Investment Management, Inc. | 5,079,141 | $90.5M | -509,116 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,844,431 | $86.3M | +1,085,969 |
By Quarter
| Quarter | Institutions | Shares | Value |
|---|---|---|---|
| Q2 2026 | 246 | 154,105,427 | $2.75B |
| Q1 2026 | 202 | 156,869,123 | $2.80B |
| Q4 2025 | 186 | 149,190,405 | $4.02B |
| Q3 2025 | 138 | 114,261,995 | $3.44B |
| Q2 2025 | 116 | 109,326,693 | $2.92B |
From the SEC's Form 13F data sets: investment managers with $100 million or more in Section 13(f) securities report their holdings each quarter, up to 45 days after it ends; a restated filing replaces the original, and values are as the managers reported them (a position whose price runs about 1,000 times below other managers', from a manager whose positions mostly do, is read as reported in thousands of dollars). The same shares can be reported by more than one manager, so totals can count some twice.
ETFs Holding CAI
| Fund | Weight of CAI | Shares (as reported) | Value (as reported) | Source updated |
|---|---|---|---|---|
| VTI Vanguard Morningstar Total Stock Market ETF | 0.00% | 4,057,769 | $103.4M | Oct 7, 2026 |
| VB Vanguard Morningstar Small-Cap ETF | 0.04% | 2,925,472 | $74.6M | Oct 7, 2026 |
| VBK Vanguard Morningstar Small-Cap Growth ETF | 0.09% | 1,684,231 | $42.9M | Oct 7, 2026 |
| IBB iShares Biotechnology ETF | 0.25% | 960,911 | $26.0M | Oct 8, 2026 |
| FXH First Trust Health Care AlphaDEX Fund | 2.13% | 882,803 | $23.9M | Oct 8, 2026 |
| SCHA Schwab U.S. Small-Cap ETF | 0.08% | 669,423 | $18.1M | Oct 8, 2026 |
| IWP iShares Russell Mid-Cap Growth ETF | 0.09% | 623,903 | $16.9M | Oct 8, 2026 |
| IWR iShares Russell Mid-Cap ETF | 0.02% | 515,704 | $14.0M | Oct 8, 2026 |
| IWF iShares Russell 1000 Growth ETF | 0.01% | 407,149 | $11.0M | Oct 8, 2026 |
| IDNA iShares Genomics Immunology and Healthcare ETF | 3.00% | 340,550 | $9.2M | Oct 8, 2026 |
| FTXH First Trust Nasdaq Pharmaceuticals ETF | 0.54% | 208,940 | $5.7M | Oct 8, 2026 |
| QGRO American Century U.S. Quality Growth ETF | 0.26% | 188,271 | $5.1M | Oct 8, 2026 |
| VONG Vanguard Russell 1000 Growth ETF | 0.01% | 181,003 | $4.6M | Oct 7, 2026 |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.00% | 169,758 | $4.6M | Oct 8, 2026 |
| FNX First Trust Mid Cap Core AlphaDEX Fund | 0.33% | 159,634 | $4.3M | Oct 8, 2026 |
From each fund's latest holdings file on record that shows CAI's listed security itself. A file counts when its line count is consistent with the fund's reported holdings count (at most twice it plus 10, or at most 1,000 lines for a reported count of exactly 10, which the data source gives many funds as a cap), read with that file or inherited from the fund's last classified file (within 20% of its line count, read within 60 days). Funds whose line for the company could not be confirmed as CAI's listed security, or that hold it through underlying funds (look-through), are not listed. Only long positions count: a fund is left out when any of its lines for CAI reports a negative weight, share count or value, or none of them above zero (a short position, or figures that disagree). Shares, value and weight are as reported in each fund's file, dated by the data source's last update of that file (not the date of the positions); the weight is CAI's share of that fund.
How to Read CAI Insider Activity
Net insider sentiment skews to the sell side over the trailing twelve months: 7 sales versus 4 buys. Insider sales carry less informational weight than buys because they are often driven by liquidity, tax planning, or pre-scheduled Rule 10b5-1 trading plans rather than negative information. The transaction type alone does not say whether a sale was made on the open market or privately, or under a 10b5-1 plan; the filing's plan checkbox and footnotes do. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.
Learn how insider trading is reported and how to read the data →
Frequently asked CAI insider trading questions
- How active are CAI insiders right now?
- Over the trailing twelve months, Caris Life Sciences, Inc. (CAI) insiders made 4 buy transactions and 7 sale transactions. Net insider sentiment over the trailing twelve months tilts to the sell side (7 sales vs 4 buys). The transaction list above shows the most recent filings; each entry includes the insider's name, transaction type, share count, and per-share price.
- What counts as an insider transaction?
- Section 16 of the Securities Exchange Act requires officers, directors, and 10% beneficial-owner shareholders to disclose changes in their holdings via Form 3 (initial statement), Form 4 (subsequent transactions, filed within two business days), and Form 5 (annual catch-up). Insider transactions cover open-market purchases and sales, exercise of stock options, gifts, and grants. The "transaction type" field on each row distinguishes these subcategories.
- Are CAI insider buys a bullish signal?
- Insider purchases (Type P, made on the open market or privately; the code covers both) carry more informational weight than insider sales: an insider must commit personal capital, and the SEC scrutinizes purchases under Rule 10b5-1 for material non-public information. Sales, by contrast, are often driven by liquidity, tax planning, or pre-scheduled 10b5-1 trading plans rather than negative information. Cluster buying (multiple insiders buying within a short window) is a stronger signal than isolated buys.
- How do CAI insider transactions affect options pricing?
- Insider transaction data does not directly drive implied volatility, but Form 4 disclosures can move single-name IV if the size or timing is unusual (e.g. a large CEO buy ahead of an earnings window). Options markets price the marginal informational content; routine transactions under pre-scheduled plans are typically ignored. For event-driven options sizing, pair the insider transaction history with the upcoming earnings calendar.